Judith Barrick, in Barnesville, OH - Occupational Therapist

Judith Barrick, is a Occupational Therapist based in Barnesville, Ohio. Judith Barrick is licensed to practice in Ohio (license number 001827) and her current practice location is 639 W Main St, Barnesville, Ohio. She can be reached at her office (for appointments etc.) via phone at (740) 425-5110.

NPI number for Judith Barrick is 1639578784 and her current mailing address is 286 Arborland Rd, Wheeling, West Virginia. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1639578784.

Contact Information

	Judith Barrick,
	639 W Main St, Barnesville, OH 43713-1039
	(740) 425-5110
	Not Available

Healthcare Provider's Profile

Full Name	Judith Barrick
Gender	Female
Speciality	Occupational Therapist
Location	639 W Main St, Barnesville, Ohio
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1639578784
Provider Enumeration Date: 08/14/2014
Last Update Date: 08/14/2014

Medical Identifiers

Medical identifiers for Judith Barrick such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1639578784	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
225X00000X	Occupational Therapist	001827 (Ohio)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Judith Barrick is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Judith Barrick, 286 Arborland Rd, Wheeling, WV 26003-9386 Ph: (304) 243-0964	Judith Barrick, 639 W Main St, Barnesville, OH 43713-1039 Ph: (740) 425-5110

News Archive

China SFDA awards Jiangsu Yanshen a new drug certificate and production license for its H1N1 vaccine

Simcere Pharmaceutical Group (NYSE: SCR) ("Simcere" or the "Company"), a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China, today announced that Jiangsu Yanshen Biological Technology Stock Co., Ltd ("Jiangsu Yanshen"), in which Simcere holds a 37.5% stake, was awarded a new drug certificate and production license from China's State Food and Drug Administration (SFDA) on September 18 for Jiangsu Yanshen's H1N1 vaccine.

PharmaEngine files NDA with Taiwan FDA for MM-398 to treat post-gemcitabine metastatic pancreatic cancer

PharmaEngine, Inc. today announced that a New Drug Application (NDA) has been submitted to the Taiwan Food and Drug Administration (TFDA) for MM-398 (irinotecan liposome injection, also known as nal-IRI) in patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy.

New online health reform source from Kaiser Family Foundation

Nearly six months since the signing of the Patient Protection and Affordable Care Act and as some key provisions are due to be implemented, the Kaiser Family Foundation today launched an online gateway providing easy access to new and comprehensive resources on the health reform law.

FLX Bio treats first patient in its Phase 1/2 clinical trial of FLX475 for treating various advanced cancers

FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist that selectively inhibits migration of regulatory T cells into the tumor microenvironment.

Judith Barrick, - Occupational Therapist in Barnesville, OH